| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.41▼ | 2.42▼ | 2.42▼ | 2.58▼ | 4.03▼ |
| MA10 | 2.43▼ | 2.43▼ | 2.48▼ | 2.35▲ | 5.72▼ |
| MA20 | 2.43▼ | 2.50▼ | 2.58▼ | 3.92▼ | 7.01▼ |
| MA50 | 2.43▼ | 2.56▼ | 2.43▼ | 6.12▼ | 7.41▼ |
| MA100 | 2.47▼ | 2.41▼ | 2.59▼ | 7.34▼ | 9.15▼ |
| MA200 | 2.57▼ | 2.89▼ | 4.97▼ | 7.04▼ | 12.82▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.004▼ | -0.034▼ | 0.038▲ | -0.660▼ |
| RSI | 35.592▼ | 36.952▼ | 41.281▼ | 33.098▼ | 33.013▼ |
| STOCH | 9.259▼ | 53.926 | 24.103 | 58.950 | 22.276 |
| WILL %R | -77.778▼ | -84.375▼ | -86.842▼ | -82.913▼ | -88.421▼ |
| CCI | -184.555▼ | -79.885 | -81.368 | -8.112 | -145.188▼ |
|
Tuesday, April 28, 2026 02:26 PM
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
|
|
Monday, April 27, 2026 06:30 AM
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...
|
|
Wednesday, April 22, 2026 11:47 AM
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to do” with the FDA’s decision to reject Replimune’s (REPL) lead candidate ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 29/04/26 | 2.51 | 2.541 | 2.335 | 2.38 | 3,899,443 |
| 28/04/26 | 2.6977 | 2.725 | 2.55 | 2.57 | 4,560,911 |
| 27/04/26 | 2.50 | 2.78 | 2.47 | 2.68 | 5,450,775 |
| 24/04/26 | 2.70 | 2.78 | 2.3701 | 2.42 | 8,764,045 |
| 23/04/26 | 2.35 | 2.96 | 2.32 | 2.85 | 19,248,092 |
| 22/04/26 | 1.94 | 2.31 | 1.875 | 2.27 | 17,814,141 |
| 21/04/26 | 2.06 | 2.06 | 1.8425 | 1.86 | 6,106,790 |
| 20/04/26 | 2.15 | 2.19 | 2.03 | 2.07 | 4,597,046 |
| 17/04/26 | 2.21 | 2.27 | 2.09 | 2.17 | 5,867,838 |
| 16/04/26 | 2.31 | 2.40 | 2.13 | 2.19 | 8,673,826 |
|
|
||||
|
|
||||
|
|